Project Grant R03HL187223
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $223K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Poughkeepsie, NY 12604, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $718,824 in project grant funding (R01HL188006) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the mechanisms by which electronic cigarette exposure drives vascular injury and atherosclerosis progression through the glutamate N-methyl-D-aspartate receptor (NMDAR) pathway in vascular smooth muscle cells. The research comprises three...
- The National Heart, Lung, and Blood Institute awarded the University of California, Davis $770,045 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate tobacco smoke-driven fibroblast reprogramming in pulmonary fibrosis. The research deciphers molecular mechanisms by which tobacco smoke promotes fibrotic remodeling in the lungs. Using proteomic and metabolomic profiling, the investigator identified tobacco smoke–induced lactate accumulation and...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $821,294 to The Trustees of Columbia University in the City of New York on September 1, 2026, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077, Project Grant R01HL179303). The award funds the VAPESCAN study, a longitudinal investigation examining early lung toxicity associated with e-cigarette versus cigarette use in young adults aged 18–50....
- The National Heart, Lung, and Blood Institute awarded Yale University $126,177 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund postdoctoral and early-career research investigating the role of intraflagellar transport protein IFT88 in smooth muscle cell phenotype and vascular remodeling. The research addresses mechanisms by which smooth muscle cells in blood vessel walls transition between differentiated and dedifferentiated phenotypes—a process...
- The National Heart Lung and Blood Institute awarded $827,439 to Lundquist Institute For Biomedical Innovation At Harbor-UCLA Medical Center on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms by which perinatal nicotine vaping exposure dysregulates pulmonary group 2 innate lymphoid cells (ILC2s) and promotes allergic asthma development in offspring. The research employs electronic nicotine delivery system (ENDS) exposure models and...
- The National Heart Lung and Blood Institute awarded the University of Utah $470,606 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of smoking-induced endothelial dysfunction associated with the ALDH2*2 genetic variant. The research employs a multidisciplinary approach integrating stem cell biology, molecular biology, toxicology, vascular physiology, and endothelial mechanobiology to understand how tobacco consumption...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $127,168 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model the effect of apolipoprotein L1 risk variants on cardiovascular disease risk in African American e-cigarette users. The research employs human induced pluripotent stem-cell-derived endothelial cells to investigate how e-cigarettes, with and without menthol, affect endothelial health in...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $232,836 on December 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomarkers of ischemic risk in adults with sickle cell disease using non-invasive quantitative neuroimaging methods. The research uses arterial spin labeling MRI and other quantitative imaging techniques to test hypotheses regarding cerebral oxygen utilization in patients with sickle cell disease...